Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kronos Bio Inc (KRON)

Kronos Bio Inc (KRON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,324
  • Shares Outstanding, K 60,094
  • Annual Sales, $ 6,290 K
  • Annual Income, $ -112,670 K
  • 60-Month Beta 1.89
  • Price/Sales 13.43
  • Price/Cash Flow N/A
  • Price/Book 0.62
Trade KRON with:

Options Overview Details

View History
  • Implied Volatility 220.67% ( +9.76%)
  • Historical Volatility 145.40%
  • IV Percentile 41%
  • IV Rank 13.34%
  • IV High 1,466.97% on 03/15/24
  • IV Low 28.89% on 07/19/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 3,759
  • Open Int (30-Day) 3,606

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.36
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.42
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +30.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9300 +34.41%
on 06/27/24
1.6000 -21.88%
on 07/16/24
+0.2400 (+23.76%)
since 06/18/24
3-Month
0.6900 +81.16%
on 05/24/24
1.6000 -21.88%
on 07/16/24
+0.2400 (+23.76%)
since 04/19/24
52-Week
0.6900 +81.16%
on 05/24/24
2.2200 -43.69%
on 07/24/23
-0.9600 (-43.44%)
since 07/19/23

Most Recent Stories

More News
5 Microcap Stocks With 65% or More Upside Potential

While they do carry higher-than-average risk, these microcaps also offer major upside potential for investors seeking startup-sized returns.

BTBT : 3.89 (+5.99%)
^BTCUSD : 66,711.76 (-0.42%)
ERJ24 : 3,144.04s (-0.63%)
GOEV : 2.30 (-2.54%)
KRON : 1.2500 (-5.30%)
OGI : 1.6500 (+1.85%)
QBTS : 1.0200 (-4.67%)
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

/PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider...

KRON : 1.2500 (-5.30%)
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

/CNW/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of...

KRON : 1.2500 (-5.30%)
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress

Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute...

KRON : 1.2500 (-5.30%)
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress

Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid...

KRON : 1.2500 (-5.30%)
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR

Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare,...

KRON : 1.2500 (-5.30%)
Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022

Data include results from preclinical studies of KB-0742 in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well...

KRON : 1.2500 (-5.30%)
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives...

KRON : 1.2500 (-5.30%)
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results

Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and...

KRON : 1.2500 (-5.30%)
Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia

Data in the second half of 2023 could potentially lead to accelerated approvalIf approved, entospletinib would be the first treatment for newly diagnosed...

KRON : 1.2500 (-5.30%)

Business Summary

Kronos Bio Inc. is a clinical-stage biopharmaceutical company. It engages in discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Kronos Bio Inc. is headquartered in San Mateo, Calif.

See More

Key Turning Points

3rd Resistance Point 1.4667
2nd Resistance Point 1.4233
1st Resistance Point 1.3367
Last Price 1.2500
1st Support Level 1.2067
2nd Support Level 1.1633
3rd Support Level 1.0767

See More

52-Week High 2.2200
Fibonacci 61.8% 1.6355
Fibonacci 50% 1.4550
Fibonacci 38.2% 1.2745
Last Price 1.2500
52-Week Low 0.6900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar